Shaping the Management of Multiple Sclerosis – The Potential for BTK Inhibitors in Clinical Practice
Released On
October 24, 2022
Expires On
October 24, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Neurology
Topic(s)
Multiple Sclerosis
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Sanofi.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward neurologists, nurse practitioners, physician assistants, and other health care professionals involved in the diagnosis and management of patients with MS.
Program Overview
Advances in the understanding of immune mechanisms that contribute to the pathophysiology of multiple sclerosis (MS) have led to the development of many disease-modifying therapies that target effector T cells, regulatory cells, B cells, and cell trafficking into the nervous system. Among these emerging pathways is use of Bruton tyrosine kinase (BTK) inhibitors, which block the actions of B cells and may affect other cell types that can facilitate inflammation. This bridging of adaptive and innate immunity separates BTK inhibition from other currently available B-cell targeting therapies, such as depletion by CD20 antibodies.
This continuing education satellite symposium program, presented at the 2022 International Congress on the Future of Neurology®, aims to update clinicians on key clinical data pertaining to current and emerging B-cell–depleting and BTK-inhibiting therapies for the treatment of patients with MS. Clinicians also can expect to learn about approaches to personalizing care.
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Review the role of Bruton’s tyrosine kinase (BTK) in the pathogenesis of multiple sclerosis (MS)
- Analyze clinical trial data for BTK inhibitors in the treatment of MS
- Develop individualized treatment plans for patients with MS
Faculty
Stephen Krieger, MD, FAAN
Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Erin Longbrake, MD, PhD
Assistant Professor of Neurology
Director, Neuroimmunology Fellowship Program
Director, Clinical Research in Neuroimmunology, Multiple Sclerosis & Other Inflammatory Brain Disease
Yale School of Medicine
New Haven, CT
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Stephen Krieger, MD, FAAN
-
- Grant/Research Support: Biogen, Bristol Myers Squibb, Novartis
- Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave Bioscience, TG Therapeutics
- Speakers’ Bureau: Biogen, EMD Serono, Genentech
- Erin Longbrake, MD, PhD
-
- Grant/Research Support: Genentech
- Consultant: Genentech, Janssen Pharmaceutical Companies, TG Therapeutics
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
-
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
- You may immediately download your certificate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and aboveSupported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or aboveOff-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.